SCCHN Clinical Trial
Official title:
Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen
In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck who have failed platinum or a platinum containing regimen. In Phase IIb, randomized control study between NC-6004 in combination with pembrolizumab versus pembrolizumab alone in the same subject population as Part 1 at the RPIIb dose identified in PIIa.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04595981 -
Chemo-embolization for Head and Neck Cancer
|
Phase 2 | |
| Enrolling by invitation |
NCT01393184 -
Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN
|
Phase 2 | |
| Completed |
NCT04107103 -
Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04925284 -
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
|
Phase 1 | |
| Recruiting |
NCT02878655 -
Evaluation of the Overall Quality of Life After the Neck Dissection Retro-spinal Sector (IIb), in Squamous Cell Carcinomas Clinical and Radiological N0 VADS
|
||
| Completed |
NCT02573259 -
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
|
Phase 1 |